Dividends & Buybacks ·
bioAffinity Technologies, Inc. announced a one-for-fifteen (1-for-15) reverse stock split of its common stock to…
BIAFWbioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. announced a one-for-fifteen (1-for-15) reverse stock split of its common stock to comply with Nasdaq’s minimum bid price requirement. The Board approved the split following shareholder authorization at the April 30, 2026 annual meeting. The effective date is August 21, 2026, at 4:01 p.m. Eastern Time, with split-adjusted trading commencing on August 24, 2026. Post-split, approximately 592,373 shares will be issued and outstanding. Fractional shares will be paid out in cash, and exercise prices for options, warrants, and RSUs will be proportionately adjusted. The company operates in the biotechnology industry, focusing on noninvasive diagnostic tests for early-stage cancer detection.